A Locked, Dimeric CXCL12 Variant Effectively Inhibits Pulmonary Metastasis of CXCR4-Expressing Melanoma Cells Due to Enhanced Serum Stability

Tomonori Takekoshi1, Joshua J. Ziarek2, Brian F. Volkman2, and Sam T. Hwang1

Abstract

The CXC chemokine receptor-4 (CXCR4) plays a critical role in cancer by positively regulating cancer cell metastasis and survival. We previously showed that high concentrations of the CXCR4 ligand, wild-type CXCL12 (wtCXCL12), could inhibit colorectal cancer metastasis in vivo, and we have hypothesized that wtCXCL12 dimerizes at high concentration to become a potent antagonist of CXCR4. To address this hypothesis, we engineered a covalently locked, dimeric variant of CXCL12 (CXCL122). Herein, we show that CXCL122 can not only inhibit implantation of lung metastasis of CXCR4-B16-F10 melanoma cells more effectively than AMD3100, but that CXCL122 also blocks the growth of established pulmonary tumors. To identify a basis for the in vivo efficacy of CXCL122, we conducted Western blot analysis and ELISA analyses, which revealed that CXCL122 was stable for at least 12 hours in serum, whereas wtCXCL12 was quickly degraded. CXCL122 also maintained its antagonist properties in vitro chemotaxis assays for up to 24 hours in serum, whereas wtCXCL12 was ineffective after 6 hours. Heat-inactivation of serum prolonged the stability and function of wtCXCL12 by more than 6 hours, suggesting enzymatic degradation as a possible mechanism for wtCXCL12 inactivation. In vitro analysis of amino-terminal cleavage by enzymes dipeptidylpeptidase IV (DPP IV/CD26) and matrix metalloproteinase-2 (MMP-2) resulted in 25-fold and 2-fold slower degradation rates, respectively, of CXCL122 compared with wtCXCL12. In summary, our results suggest CXCL122 possesses greater potential as an antimetastatic drug as compared with AMD3100 or wtCXCL12, potentially due to enhanced serum stability in the presence of N-terminal degrading enzymes. Mol Cancer Ther; 11(11); 2516–25. ©2012 AACR.

Introduction

Cancer metastasis to vital organs represents the major source of mortality in cancer. Metastasis is a complex process that is dependent upon many factors, including tumor cell properties, the tumor microenvironment, and host tumor immunity. Chemokine signaling plays a crucial role in cancer metastasis, neoangiogenesis, and proliferation as well as infiltration of tumor-associated immune cells (1, 2). We have focused on CXC chemokine receptor-4 (CXCR4), which is upregulated in at least 23 different cancers (3). We previously showed that CXCR4 enhances β1 integrin-dependent pulmonary metastasis of B16 melanoma cells 6- to 10-fold following intravenous inoculation (4, 5). We also showed that T22, a specific CXCR4 inhibitor, effectively blocked pulmonary dissemination of CXCR4-expressing B16 cells following tail vein inoculation (4), suggesting that blocking CXCR4 may be an effective strategy for preventing lung metastasis.

Recently, we reported that exogenous administration of CXCL12, the ligand of CXCR4, inhibits colorectal cancer metastasis (6). CXCL12 exists in a monomer–dimer equilibrium in which both states bind CXCR4 and stimulate a calcium response, but only the monomeric variant promotes cell migration (7, 8). We previously engineered a covalently locked, dimeric variant of CXCL12 (CXCL122; ref. 8) and showed that intraperitoneal administration inhibited the metastasis of CXCR4-overexpressing colon cancer cells to the liver (6). CXCL122 was a more potent inhibitor of colorectal metastasis than wtCXCL12. Consequently, CXCL122 diminished pulmonary implantation following tail vein injection of B16 melanoma cells (6). WtCXCL12, however, exhibits a half-life on the order of minutes (9) and is degraded by numerous enzymes, including matrix metalloproteinase-2 (MMP-2; ref. 10) and dipeptidylpeptidase IV (DPP IV/CD26; ref. 11), which may render wtCXCL12 a poor choice as a therapeutic inhibitor of CXCR4.
Herein, we show that intravenous CXCL12 treatment inhibited initial pulmonary dissemination of CXCR4-expressing B16 more effectively than the U.S. Food and Drug Administration (FDA)-approved CXCR4 inhibitor, AMD3100. Importantly, CXCL12 also inhibited the growth of established CXCR4-expressing B16 lung metastatic tumors, suggesting that it may have utility in treating established metastasis in humans. CXCL12 was much more stable than wtCXCL12 in mouse serum, maintaining its inhibitory function in chemotaxis assays for at least 12 hours. CXCL12 showed enhanced stability in the presence of DPPIV/CD26 and MMP-2 N-terminal degrading enzymes, which likely contributed to the superior activity of CXCL12 in the presence of mouse serum. These data suggest that CXCL12 has a potential for clinical use in the treatment of metastatic tumors.

Materials and Methods

**Animals and cell lines**

Female C57BL/6 mice (8–12 weeks old) were purchased from Charles River Laboratories or The Jackson Laboratory and used in accordance with the guidelines of the Animal Use and Care Committee of the Medical College of Wisconsin. B16-F1 melanoma cells are a kind gift from Dr. Kiyoshi Ariizumi (Dermatology, UT Southwestern Medical Center, Dallas, TX; ref. 12). Syngeneic B16-F1 melanoma cells (originally obtained from the NCI-Frederick Cancer Research and Development Center) and B16-F10 melanoma cells were grown in Dulbecco’s Modified Eagle’s Media (Invitrogen) with 10% heat-inactivated FBS and supplements as previously described (13). Neither the B16-F10 melanoma cell nor the B16-F1 melanoma cell line have been authenticated since acquisition, although both produce melanin pigment as expected for melanoma cell lines. THP-1 cells were obtained from American Type Culture Collection but have not been authenticated since acquisition.

**Retroviral transduction of B16-F1 and B16-F10 melanoma cells**

Human CXCR4 cDNA (14), a gift from Dr. E. Berger (National Institute of Allergy and Infectious Diseases, Bethesda, MD), was subcloned into the pLNCX2 retroviral vector (Clontech). Using this vector, B16-F1 melanoma cells and B16-F10 cells were transduced as previously described (13) to yield CXCR4-B16 cells.

**Construction of plasmids**

Human CXCL12 and CXCL12 were cloned from the previously described pQE30 vectors (7, 8) into a PET28a vector that incorporates a N-terminal His tag and *Saccharomyces cerevisiae* SUMO protein (Smt3). The final, purified CXCL12 protein constructs possess a native N-terminal sequence for proper function. All expression vector inserts were confirmed by DNA sequencing.

**Protein expression and purification**

Smt-CXCL12 expression vectors were transformed into *Escherichia coli* strain BL21 (DE3), and cells were grown at 37°C in Luria-Bertani medium. Protein expression was induced by the addition of isopropyl-β-D-thiogalactopyranoside to a final concentration of 1 mmol/L when the culture reached an OD600 of 0.6. After incubation at 37°C for 6 hours, cells were pelleted at 5,000 × g and stored at −80°C until further processing. Cell pellets were resuspended in 10 mL of a buffer containing 50 mmol/L Na2 PO4 (pH 8.0), 300 mmol/L NaCl, 10 mmol/L imidazole, 1 mmol/L phenylmethylsulfonyl fluoride, and 0.1% (v/v) 2-mercaptoethanol. Resuspended cells were lysed by 3 passages through a French press. Inclusion bodies were collected by centrifugation at 15,000 × g, and the supernatant was discarded. The insoluble inclusion body pellet was dissolved in buffer AD (6 mol/L guanidinium chloride, 50 mmol/L Na2PO4 (pH 8.0), 300 mmol/L NaCl, 10 mmol/L imidazole) and batch loaded onto 2 mL of Ni-NTA resin (Qiagen). After 30 minutes the column was washed with 4 × 10 mL of buffer AD followed by elution with a buffer containing 6 mol/L guanidinium chloride, 50 mmol/L sodium acetate (pH 4.5), 300 mmol/L NaCl, and 10 mmol/L imidazole. The eluate was pooled and refolded via dropwise dilution into a 20 mmol/L Tris (pH 8.0), 10 mmol/L cysteine, and 0.5 mmol/L cystine solution. Following overnight refolding, the solution was concentrated by ultrafiltration (MWCO 10 kDa), and the tagged cleaved by incubation with 500 µg Ulp1 protease at 30°C for 12 hours. The Smt-tag was separated from the protein using cation-exchange chromatography. Samples were batch loaded onto SP Sepharose Fast Flow resin (GE Healthcare UK Ltd.) and washed with Tris (pH 8.0), 50 mmol/L NaCl to remove the Smt-tag. Protein was eluted with 20 mmol/L Tris (pH 8.0) containing 2 mol/L NaCl. Finally, samples were purified to more than 98% homogeneity using reverse-phase high-performance liquid chromatography with a 30-minute gradient from 30% to 60% ACN in aqueous 0.1% trifluoroacetic acid. CXCL12 variants were frozen, lyophilized, and stored at −20°C. Purity, identity, and molecular weight were verified by matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry and nuclear magnetic resonance spectroscopy.

**Inoculation of transduced cell lines**

CXCR4-B16 and pLNCX2-B16 cells in exponential growth phase were harvested and washed 2 times in PBS before injection. Cell viability was more than 90% as determined by trypan blue dye exclusion. For intravenous injection, 4 × 10⁵ CXCR4-B16 or pLNCX2-B16 cells in 200 µL were injected into the tail veins of mice. Images are representative of experimental trends.

**Luciferase assay**

Luciferase activity was measured using a luciferase reporter assay system (Promega). Lungs from each animal were homogenized in 1 mL of lysis buffer, of which 100 µL...
CXCL12 variants were diluted in HBSS/HEPES buffer and added to each well for a 500 nmol/L final concentration. Calcium response was measured by fluorescence spectroscopy every 1.5 seconds for a total of 180 seconds using a FlexStation 3 Microplate Reader (Molecular Devices). Baseline fluorescence was measured 30 seconds before addition of ligand. Values were subsequently normalized to the average baseline fluorescence. Experiments were recorded in quadruplicate on 2 separate days.

**DPPIV/CD26 degradation assay**

Recombinant human DPPIV/CD26 was purchased from R&D Systems. Degradation reactions (n = 3) were composed of 0.2 ng/μL DPPIV/CD26, 10 μmol/L wtCXCL12 (or 5 μmol/L CXCL122), 2 μmol/L Smt3, and 25 mmol/L Tris (pH 8). At the indicated time points, 1 μL aliquots were quenched with 4 μL sinalpinic acid solution and spotted on a MALDI plate. Five spectra, each composed of 100 laser shots, were collected using a Voyager-DE Pro MALDI-TOF spectrometer (PerSeptive Biosystems) for each sample. The intensity of full-length CXCL12 or CXCL122 was normalized to the Smt3 internal standard. Sample half-life was then calculated using non-linear regression (ProFit).

**MMP-2 degradation assay**

Recombinant human MMP-2 was purchased from R&D Systems. MMP2 was activated by incubation with 1 mmol/L p-aminophenylmercuric acetate in TCNB buffer [50 mmol/L Tris (pH 7.4), 10 mmol/L CaCl2, 150 mmol/L NaCl, and 0.05% (w/v) Brij 35] for 1 hour at 37°C. Reaction samples (n = 3) were composed of 1.4 ng/μL MMP-2 and 10 μmol/L Smt-wtCXCL12 (or 5 μmol/L Smt-CXCL122) in TCNB buffer. At the indicated time points, aliquots were quenched by mixing 1:1 with protein loading buffer and heating to 95°C for 5 minutes. Samples were then stored at −20°C. Before SDS-PAGE, samples were mixed with 1.46 mol/L 2-mercaptoethanol and heated to 95°C for 5 minutes. SDS-PAGE was conducted on a 15% acrylamide gel, and bands were visualized by Coomassie Blue stain. Bands were quantified using a ChemiDoc XRS Molecular Imager (BioRad), and data were fitted to a half-life equation using nonlinear regression (ProFit).

**Results**

**CXCL122 is a more effective inhibitor of lung metastasis than AMD3100**

We previously showed that CXCL122 is an effective inhibitor of CXCR4-B16-F1 cell lung implantation (6). Herein, we used the more tumorigenic B16-F10 cell line that was transduced with CXCR4 (referred to as CXCR4-

---

**ELISA**

A human CXCL12/SDF-1 ELISA kit was purchased from R&D Systems and was used for measuring wtCXCL12 or CXCL122 concentration in mouse serum (Sigma) following manufacturer’s protocol.

**Western blotting**

Mouse serum samples containing wtCXCL12 or CXCL122 were loaded onto 4% to 20% Mini-Protean TGX following manufacturer’s protocol.

**Calcium flux assay**

CXCR4-B16-F10 cells (2 × 10⁵) were harvested, washed by PBS 2 times, and resuspended in 96-well white-walled plates (BD Biosciences Discovery Labware). FLIPR Calcium 4 Assay Kit (Molecular Devices) diluted in HEPES Buffered Saline Solution (HBSS) supplemented with 20 mmol/L HEPES buffer and 0.1% (w/v) BSA was added to the plate as per manufacturer’s instructions. For inhibition experiments, cells were additionally treated with 5 μmol/L AMD3100. Plates were centrifuged at 200 × g for 5 minutes and then incubated in 37°C for 30 minutes. Calcium response was measured by fluorescence spectroscopy every 1.5 seconds for a total of 180 seconds using a FlexStation 3 Microplate Reader (Molecular Devices). Baseline fluorescence was measured 30 seconds before addition of ligand. Values were subsequently normalized to the average baseline fluorescence. Experiments were recorded in quadruplicate on 2 separate days.
B16-F10). CXCR4-B16-F10 cells (4 × 10^5 cells/200 µL including drug) were preincubated with various concentrations of CXCL12, wtCXCL12, or AMD3100 and injected intravenously into the tail veins of female C57BL/6 mice (Fig. 1A). An equivalent dose of CXCL12, wtCXCL12, or AMD3100 was administered the following day. As shown in Fig. 1B, treatment with either 0.5 µmol/L or 5 µmol/L CXCL12 strongly inhibited CXCR4-B16-F10 lung metastasis. In contrast, although wtCXCL12 exhibited a dose–response trend, it was unable to significantly prevent CXCR4-B16-F10 lung metastasis (Fig. 1C). We next compared the effectiveness of CXCL12 with AMD3100, an FDA-approved CXCR4-antagonist in clinical use for stem-cell mobilization (15–17). Neither the equivalent molar concentration (5 µmol/L, 200 µL) nor mass weight (15.9 µg/200 µL; 100 µmol/L) of AMD3100
(MW; 794.47 Da) to 5 μmol/L of CXCL12 (MW; 15,962 Da) significantly reduced CXCR4-B16-F10 lung metastasis (Fig. 1D). A macroscopic comparison of lung metastases in the presence of these CXCR4 inhibitors is depicted in Fig. 1E. We also measured CXCL12 inhibition of metastasis using the less tumorigenic B16-F1 cells. We found that 0.5 μmol/L, but not 0.05μmol/L, of CXCL12 inhibited enhanced CXCR4-B16-F1 lung metastasis and that this dose of CXCL12 did not affect the lower lung metastasis rates of CXCR4-negative pLNCX2-B16-F1 cells (Supplementary Fig. S1). Overall, these results indicate that CXCL12 more effectively prevented lung metastasis of CXCR4-expressing melanoma cells than did AMD3100 in a preimplantation model of lung metastasis.

**CXCL12 induces calcium response in CXCR4-expressing B16 cells**

We previously showed that CXCL12 induced CXCR4-mediated calcium response but inhibited chemotaxis in both THP-1 monocytes and HCT116 colorectal cancer cells (6, 7). To confirm that CXCL12 actively signaled via CXCR4 in CXCR4-B16 cells, we monitored the calcium response induced by 500 nmol/L protein in the presence or absence of 5 μmol/L AMD3100. Both wtCXCL12 and CXCL12 induced a robust calcium response in CXCR4-B16-F1 cells that was partially inhibited by AMD3100 (Fig. 1F, Supplementary Fig. S2). In contrast, pLNCX2-B16-F1 control cells, that lacked CXCR4, were unable to elicit a response (Supplementary Fig. S2).

**CXCL12 inhibits outgrowth of established CXCR4-B16 metastatic lesions in lung**

We next asked if CXCL12 also prevented the outgrowth of established CXCR4-B16 metastatic lesions in the lung. We previously showed that the CXCL12 cyclic peptide antagonist, T22, was ineffective for inhibiting established tumors (4, 5). CXCR4-B16-F10 cells (4 x 10⁵) were injected intravenously into tail veins and allowed to establish for 5 days. On days 5 and 6, mice were treated intravenously with either 5 μmol/L CXCL12 or vehicle control (Fig. 2A). Interestingly, tumor burden of CXCL12-treated mice were significantly less than that of vehicle-treated mice by approximately 50% (Fig. 2B and C). We also found a striking difference in the number of locally invasive lesions in the thoracic cavity of vehicle-versus CXCL12-treated mice, suggesting that CXCL12...
may reduce local metastatic spread (Fig. 2D and E). Taken together, our results suggest that CXCL12₂ not only prevents tumor engraftment, but that it also inhibits established pulmonary tumor outgrowth and reduces locally invasive metastastic spread of tumors.

Enhanced m stability of CXCL12₂

Next, we sought to explain why dimeric CXCL12 might be a more effective inhibitor in vivo. To determine if mouse serum stability was an issue, we incubated 10 µmol/L wtCXCL12 and CXCL12₂ in 90% normal mouse serum for up to 12 hours. Western blot analysis using human CXCL12 ELISA detection antibody showed rapid degradation of wtCXCL12 that was consistent with previous reports (Fig. 3A; Supplementary Fig. S3) for full-length blot. Surprisingly, CXCL12₂ exhibited little degradation after 12 hours incubation. The degradation of wtCXCL12 was abrogated in the presence of heat-inactivated normal mouse serum and monitored by Western blot analysis. Cropped bands are shown; full-length blots are presented in Supplementary Figs. S3 and S4.

We next asked how long CXCL12₂ could be incubated with serum before it was ineffective at inhibiting wtCXCL12-induced chemotaxis. CXCL12₂ samples were mixed with 90% mouse serum for the indicated time points (0–24 hours); the samples were then diluted for the chemotaxis assay to final conditions of 10 or 100 nmol/L wtCXCL12. CXCL12₂ maintained functional inhibition of wtCXCL12-induced migration for up to 24 hours (Fig. 4E). Higher concentrations of CXCL12₂ (100 nmol/L) strongly inhibited chemotaxis induced by wtCXCL12 as compared with lower concentrations of CXCL12₂ (10 nmol/L; Fig. 4E). CXCL12₂ inhibited 10 nmol/L wtCXCL12-induced migration with an IC₅₀ = 19 ± 6.4 nmol/L (Supplementary Fig. S5), highlighting the prolonged stability of CXCL12₂.

Functional stability of CXCL12₂ in mouse serum

We next asked how long wtCXCL12 remained functional in mouse serum by conducting Transwell chemotaxis assays using THP-1 monocytes. After confirming that chemotaxis buffer containing 1% serum showed no tendency for wtCXCL12 degradation as measured by ELISA (data not shown), we used 10 nmol/L wtCXCL12 in 1% serum as a positive control (labeled as “fresh” in Fig. 4D). Samples of wtCXCL12 were incubated in 90% serum for various time points (0–6 hours). The samples were then diluted to final conditions of 10 nmol/L wtCXCL12 in 1% mouse serum for the chemotaxis experiment. WtCXCL12 gradually exhibited reduced chemotactic activity during incubation with mouse serum and was almost completely inactive after 6 hours (Fig. 4D). Heat-inactivation of serum inhibited the functional degradation of wtCXCL12 (Fig. 4D).

Resistance of CXCL12₂ to MMP-2 and DPPIV/CD26 proteases

Segers and colleagues (20) previously showed that a SUMO-CXCL12 fusion protein could be used as a sensitive probe of MMP-2-induced cleavage of the chemokine N-terminus. To monitor N-terminal degradation of wtCXCL12, we generated SUMO-tagged (Smt)-wtCXCL12 and incubated it with mouse serum. Smt-wtCXCL12 degradation in serum was detected by anti-CXCL12 Ab (Fig. 5A; Supplementary Fig. S4 for full-length blot). MMP-2 and DPPIV/CD26 are 2 amino-peptidases that are known to cleave the wtCXCL12 N-terminus at distinct amino acid residues (Fig. 5B). MMP-2 recognizes CXCL12 with its hemopexin C domain and cleaves the peptide bond between Ser⁴ and Leu⁵ (10). To test whether or not CXCL12₂ possessed enhanced resistance to MMP-2 degradation, 10 µmol/L Smt-CXCL12 and 5 µmol/L Smt-CXCL12₂ were incubated with 1.4 ng/µL human MMP-2. Analysis of the time course showed that the half-life of

Figure 3. WtCXCL12 is quickly degraded in mouse serum, but CXCL12₂ is stable for at least 12 hours. A, CXCL12₂ and wtCXCL12 were incubated with 90% normal mouse serum. Western blot analysis was conducted using anti-hCXCL12 ELISA antibody (R&D Systems ELISA DuoSet). Representative of 2 independent experiments with similar results. B, WtCXCL12 was also incubated with heat-inactivated normal mouse serum and monitored by Western blot analysis. Cropped bands are shown; full-length blots are presented in Supplementary Figs. S3 and S4.
CXCL12$_2$ (130 minutes) is twice that of wtCXCL12 (60 minutes; Fig. 5C and D).

DPPIV/CD26 cleaves CXCL12 between Pro2 and Val3 (Fig. 5B; 21) but cannot digest Smt-wtCXCL12 (data not shown). Therefore, we incubated 10 nmol/L wtCXCL12 and 5 nmol/L CXCL12$_2$ with 0.2 ng/mL human DPPIV/CD26 and monitored the degradation of full-length proteins by MALDI-TOF mass spectrometry. For each time point, the intensity of full-length CXCL12 constructs was normalized to a Smt3 internal standard. As was expected, most of wtCXCL12 was cleaved within 1 hour by DPPIV/CD26 with a half-life of 26.5 ± 8.7 minutes. Surprisingly, CXCL12$_2$ was degraded 25-fold more slowly with a half-life of 665 ± 888 minutes (Fig. 5E). In summary, the correlation between N-terminal cleavage and serum-mediated degradation suggests aminopeptidases may be the rate-limiting step for the degradation of full-length CXCL12 and that CXCL12$_2$ may owe its long serum half-life to its resistance to degradation by N-terminal peptidases, such as DPPIV/CD26 and MMP2.

**Discussion**

CXCR4 and CXCL12 have become a major avenue of cancer research since Muller and colleagues established a role for this chemokine receptor/ligand pair in cancer metastasis (22). CXCR4 is upregulated in at least 23 different cancers (3) and is associated with a clinical poor prognosis (23, 24). We reported that CXCR4 activation upregulates b1 integrin function in B16 melanoma cells, enhancing their ability to adhere to the vessel wall, and thereby increasing the risk for lung metastasis (5). Others reported that CXCR4-CXCL12 signaling also promotes lung metastasis through stromal cells (16, 25). For example, CXCR4 recruits myeloid dendritic cells, which enhance tumor growth, angiogenesis, and micrometastasis (25). Mice with CXCR4$^{-/-}$ stromal cells
may be a result of the dimer's ability to inhibit chemotaxis and actin remodeling, both of which are likely required for metastatic cells to move from the lung endothelium to the lung parenchyma. These effects on cell movement and shape may also explain the ability of the dimer to block local invasion of B16 cells into the chest cavity (Fig. 2). Further studies are warranted to refine the mechanism by which CXCL12 engages the metastatic process.

Of note, CXCL12 treatment also inhibited the growth of 5-day-old established lung tumors. We previously showed that T22 strongly diminished cell metastasis if used in a pretreatment model (i.e., before tumor cell dissemination), but was ineffective at inhibiting the outgrowth of established tumors (5). As increasing evidence supports the role of local CXCR4 expression by stromal cells and immune cells in the establishment and growth of pulmonary metastasis, this suggests that CXCL12 can potentially influence tumor growth and micrometastasis by affecting both CXCR4+ tumor cells and CXCR4+ stromal cells. On the basis of our current data (Fig. 2D and E), the exciting possibility exists that CXCL12 can mitigate locally invasive metastatic disease.

Delivery of active compound to the target organ is a major challenge in drug development. In particular, protein- or peptide-based therapies suffer from high rates of serum and liver degradation (26–29). Indeed, CXCL12 and other chemokines have extremely short half-lives in solution (9, 30, 31). Our Western blot analysis, ELISA, and chemotaxis analysis confirmed that wtCXCL12 is quickly degraded in mouse serum, but that CXCL12 was stable for at least 24 hours. The CXCL12 N-terminus is critical for receptor activation (32) and is cleaved into an inactive form by serum proteases (33). Herein, mass spectrometry revealed that DPPIV/CD26 easily cleaved the N-terminus of wtCXCL12, whereas the rate of CXCL12 processing was 25-fold slower, suggesting a mechanism for the enhanced serum stability of CXCL12. MMP-2–mediated cleavage of CXCL12 was also reduced and showed a 2-fold slower rate of degradation compared with wtCXCL12. Both enzymes are multilomain proteases that rely on first recognizing the structured chemokine domain to orient the N-terminus in the active site of the catalytic domain (10, 20). One possibility is that the enhanced stability of CXCL12 results from an inability of the enzyme recognition domains to bind dimeric CXCL12, which is a question worthy of further study. Because both DPPIV/CD26 and MMP-2 are secreted in the tumor microenvironment (34), the showed resistance of CXCL12 to cleavage by these 2 enzymes would predict enhanced stability of CXCL12 in vivo. In addition to MMP-2 and DPPIV/CD26, CXCL12 is recognized by numerous other proteases, such as MMPs 1, 3, 9, 13, and 14 (10), cathepsin G (35), and elastase (36), that are upregulated in the tumor environment of nearly all cancer types (37). Although, treatment with wtCXCL12 would be ineffective under these conditions, CXCL12 may be much more efficient as a therapeutic agent in the presence of these various proteases.

Figure 5. CXCL12 is resistant to both MMP-2 and DPPIV/CD26 cleavage. A, histidine-tagged Smt-wtCXCL12 was incubated with mouse serum and heat-inactivated mouse serum. The Western blot analysis was conducted using an anti-hCXCL12 antibody (R&D Systems ELISA DuoSet). B, MMP-2 cleaves CXCL12 between Ser4 and Leu5, whereas DPPIV/CD26 cleaves between Pro2 and Val3. C, cleavage reactions of 10 μmol/L Smt-wtCXCL12 (left) and 5 μmol/L Smt-CXCL12 (right) in the presence of 1.4 ng/mL human MMP-2 were assessed by reducing SDS-PAGE. Reactions were quenched at the indicated time points and quantified using densitometry to yield half-lives for Smt-wtCXCL12 (81 ± 9 minutes) and Smt-CXCL12 (129 ± 26 minutes; D). Representative of 2 independent experiments with similar results (n = 3). E, 10 μmol/L CXCL12 and 5 μmol/L CXCL12 were incubated with 0.2 ng/mL human DPPIV/CD26 for the indicated time points and analyzed by MALDI-TOF mass spectrometry. For each mass spectrometry spectra, the intensity of the full-length CXCL12 variants was normalized to an internal Smt3 standard. The half-lives of wtCXCL12 and CXCL12 were 26.5 ± 8.7 minutes and 665 ± 88 minutes, respectively. Representative of 2 independent experiments with similar results (n = 3).
In summary, CXCL12, but not wtCXCL12, strongly inhibited CXCR4-expressing melanoma lung metastasis. Furthermore, CXCL12 was more effective than AMD3100, the only FDA-approved CXCR4 antagonist (38). Administration of CXCL12 also reduced the growth of established CXCR4-expressing metastatic lesions. While wtCXCL12 was easily degraded in mouse serum, CXCL12 had much greater stability, in part due to slower cleavage rates of DPPIV/CD26 and MMP-2. These data support the potential utility of CXCL12 as therapy for CXCR4-expressing metastatic tumors.

Disclosure of Potential Conflicts of Interest
B.F. Volkman has an ownership interest (including patents) in US Patent 7,923,016. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions
Conception and design: J.J. Ziarek, B.F. Volkman, S.T. Hwang
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): T. Takekoshi, J.J. Ziarek.

References

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): T. Takekoshi, J.J. Ziarek, S.T. Hwang
Writing, review, and/or revision of the manuscript: T. Takekoshi, J.J. Ziarek, B.F. Volkman, S.T. Hwang
Study supervision: B.F. Volkman, S.T. Hwang

Acknowledgments
The authors thank Drs. Xuesong Wu and Gyorgy Paragh (Department of Dermatology, MCW) for their advice and technical support.

Grant Support
These studies were supported by Advancing Healthier Wisconsin Research Funds (S.T. Hwang), a MCW/Froedtert Cancer Center Collaborative Research Fellowship (T. Takekoshi), MCW Cancer Center Interdisciplinary Fellowship (J.J. Ziarek), Ann’s Hope Foundation for Melanoma (S.T. Hwang), and NIH grant AI058072 (B.F. Volkman).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 18, 2012; revised July 16, 2012; accepted July 30, 2012; published OnlineFirst August 6, 2012.


A Locked, Dimeric CXCL12 Variant Effectively Inhibits Pulmonary Metastasis of CXCR4-Expressing Melanoma Cells Due to Enhanced Serum Stability

Tomonori Takekoshi, Joshua J. Ziarek, Brian F. Volkman, et al.